|Comparison of pharmacological modulation of APP metabolism in primary chicken telencephalic neurons and in a human neuroglioma cell line.|
|Jump to Full Text|
|PMID: 20603724 Owner: NLM Status: MEDLINE|
|Sequential cleavage of amyloid precursor protein (APP) by β- and γ-secretases and the formation of Aβ peptides are pivotal for Alzheimer's disease. Therefore, a large number of drugs has been developed targeting APP metabolism. However, many pharmacological compounds have been identified in vitro in immortalized APP overexpressing cell lines rather than in primary neurons. Here, we compared the effect of already characterized secretase inhibitors and modulators on Aβ formation in primary chicken telencephalic neurons and in a human neuroglioma cell line (H4) ectopically expressing human APP with the Swedish double mutation. Primary chicken neurons replicated the effects of a β-secretase inhibitor (β-secretase inhibitor IV), two γ-secretase inhibitors (DAPM, DAPT), two non-steroidal-anti-inflammatory drugs (sulindac sulfide, CW), and of the calpain inhibitor calpeptin. With the exception of the two γ-secretase inhibitors, all tested compounds were more efficacious in primary chicken telencephalic neurons than in the immortalized H4 cell line. Moreover, H4 cells failed to reproduce the effect of calpeptin. Hence, primary chicken telencephalic neurons represent a suitable cell culture model for testing drugs interfering with APP processing and are overall more sensitive to pharmacological interference than immortalized H4 cells ectopically expressing mutant human APP.|
|Stefan Czvitkovich; Stephan Duller; Else Mathiesen; Klaus Lorenzoni; Bruno P Imbimbo; Birgit Hutter-Paier; Manfred Windisch; Robert Wronski|
Related Documents :
|12742724 - A modified microstamping technique enhances polylysine transfer and neuronal cell patte...
11164764 - Adult human olfactory stem cells.
18465204 - Recombinant epf/chaperonin 10 promotes the survival of o4-positive pro-oligodendrocytes...
8565824 - Glide directs glial fate commitment and cell fate switch between neurones and glia.
21889614 - In vitro evaluation of co-exposure of arsenium and an organic nanomaterial (fullerene, ...
3720114 - Effects of hypoxia on the embryogenesis of congenital vertebral malformations in the mo...
|Type: Comparative Study; Journal Article Date: 2010-07-06|
|Title: Journal of molecular neuroscience : MN Volume: 43 ISSN: 1559-1166 ISO Abbreviation: J. Mol. Neurosci. Publication Date: 2011 Mar|
|Created Date: 2011-02-21 Completed Date: 2011-07-21 Revised Date: 2011-07-27|
Medline Journal Info:
|Nlm Unique ID: 9002991 Medline TA: J Mol Neurosci Country: United States|
|Languages: eng Pagination: 257-67 Citation Subset: IM|
|JSW Lifesciences GmbH, Parkring 12, 8074, Grambach, Austria.|
|APA/MLA Format Download EndNote Download BibTex|
Amyloid Precursor Protein Secretases
antagonists & inhibitors,
Amyloid beta-Peptides / genetics, metabolism
Amyloid beta-Protein Precursor / genetics, metabolism*
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
Aspartic Acid Endopeptidases / antagonists & inhibitors, metabolism
Calpain / metabolism
Cell Line, Tumor
Culture Media, Conditioned / chemistry
Glioma / metabolism*
Neurons / cytology, drug effects, metabolism*
Telencephalon / cytology*, metabolism
|0/Amyloid beta-Peptides; 0/Amyloid beta-Protein Precursor; 0/Anti-Inflammatory Agents, Non-Steroidal; 0/Culture Media, Conditioned; EC 3.4.-/Amyloid Precursor Protein Secretases; EC 3.4.22.-/Calpain; EC 3.4.23.-/Aspartic Acid Endopeptidases|
Journal ID (nlm-ta): J Mol Neurosci
Publisher: Humana Press Inc, New York
© The Author(s) 2010
Received Day: 30 Month: 4 Year: 2010
Accepted Day: 18 Month: 6 Year: 2010
Electronic publication date: Day: 6 Month: 7 Year: 2010
pmc-release publication date: Day: 6 Month: 7 Year: 2010
Print publication date: Month: 3 Year: 2011
Volume: 43 Issue: 3
First Page: 257 Last Page: 267
PubMed Id: 20603724
Publisher Id: 9416
|Comparison of Pharmacological Modulation of APP Metabolism in Primary Chicken Telencephalic Neurons and in a Human Neuroglioma Cell Line|
|Bruno P. Imbimbo2|
1JSW Lifesciences GmbH, Parkring 12, 8074 Grambach, Austria
2Research and Development, Chiesi-Farmaceutici S.p.A., Via Palermo, 26/A, 43100 Parma, Italy
Alzheimer's disease (AD) is the most abundant age-related form of dementia. Insoluble amyloid plaques consisting of fibrillar Aβ42 aggregates are one of the hallmarks of Alzheimer's pathology (Hardy and Selkoe 2002).
Aβ peptides are generated by β- and γ-secretase-mediated cleavage of the amyloid precursor protein (APP), whereas α-secretase activity produces only non-amyloidogenic APP fragments and prevents Aβ production (Haass 2004). The N-terminus of the Aβ domain is cleaved by β-secretase (BACE-1), a step which is essential for the formation of all Aβ peptides including Aβ38, Aβ40, and Aβ42 (Cole and Vassar 2008). The γ-secretase is a protein complex consisting of four subunits, presenilin 1 (PS1) or PS2, APH-1a or APH-1b, PEN-2, and nicastrin, and cuts APP at the intramembranous C-terminal end of the Aβ domain (Wolfe 2006). Aβ42 has the biophysical property to aggregate fast and to form soluble oligomers as well as fibrillar structures, in contrast to Aβ40 and other Aβ peptides (Dahlgren et al. 2002; Walsh and Selkoe 2007). Indeed, soluble Aβ42 oligomers were identified as major pathological source causing neuronal toxicity and cognitive impairment (Haass and Selkoe 2007). In humans, Aβ42 levels are elevated in the cerebral cortex in both sporadic and familiar forms of AD. Mutations either directly in the APP gene, such as the Swedish double mutation at K595N/M596L in human APP (Citron et al. 1992; Mullan 1992; Mullan et al. 1992; Citron et al. 1995) or in presenilin genes (De Strooper 2007) elevate total Aβ42 content by increasing β- or γ-secretase-mediated APP cleavage. Thus, Aβ42 formation plays a pivotal role in AD.
In recent years, numerous pharmacological substances have been developed that either inhibit or modulate β- and γ-secretase activity to reduce Aβ production (Ghosh et al. 2008; Imbimbo 2008; Wolfe 2008; Silvestri 2009). However, many in vitro screens aiming to identify substances that alter APP metabolism have been performed in neuronal or non-neuronal cell lines highly overexpressing human wildtype or mutant APP. In contrast to immortalized cell lines, primary neurons produce endogenous levels of APP, undergo differentiation, and form functional synapses and thus exhibit a more physiological system for drug testing.
Primary chicken neurons fulfill the criteria that are required for analyzing APP processing. First, chicken embryos express the long APP751 and APP695 variants during development, which share 93% sequence identity with human APP (Carrodeguas et al. 2005; Sarasa and Pesini 2009). The human and chick Aβ42 sequences are identical in contrast to rodent Aβ domains, which differ in several amino acids from the human sequence. In addition, chick embryos express the essential enzyme machinery required for both amyloidogenic and non-amyloidogenic processing of APP including α-, β-, and γ-secretases (Carrodeguas et al. 2005; Sarasa and Pesini 2009). Indeed, primary cultures of chicken telencephalic neurons secrete detectable levels of Aβ1-38, Aβ1-40, Aβ1-42, and soluble APP into their cell supernatant (Esselmann et al. 2004; Leuchtenberger et al. 2009).
In this study, we examined primary chicken telencephalic neurons and a human neuroglioma cell line overexpressing human APP695 with the Swedish double mutation as cell culture models for testing compounds that interfere with APP processing. Therefore, substances previously described to inhibit or modulate APP cleavage were administered, and effects on Aβ38, Aβ40, and Aβ42 formation were evaluated.
The following compounds were included in the study: CW (3,5-bis(4-nitrophenoxy)benzoic acid), DAPM (N-(N-3,5-difluorophenacetyl)-L-alanyl-S-phenylglycine methyl ester), DAPT (N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester), calpeptin (benzyloxycarbonylleucyl-norleucinal), sulindac sulfide ((Z)-5-fluoro-2-methyl-1-[p-(methylthio)benzylidene]indene-3-acetic acid), and β-secretase inhibitor IV (all Calbiochem). All compounds were dissolved in dimethyl sulfoxide. The amount of vehicle was kept constant for all concentrations of a respective compound.
For primary chicken telencephalic cultures, Nu Serum was purchased from Becton Dickinson (BD). All other cell medium components, unless indicated, were purchased from Lonza.
Preparation of chicken telencephalic neurons was performed according to Pettmann et al. 1979 with modifications. Embryonic day 8 (E8) embryos from fertilized Lohman Brown hybrid chicken eggs were isolated, and telencephalic neurons were mechanically dissociated using a sterile nylon sieve with pore size 100 μM (BD Falcon). Neurons were maintained in Dulbecco's Modified Eagles Medium containing 4.5 g glucose/l, 5% Nu Serum, 0.01% gentamicin, and 2 mM L-glutamine.
For the Aβ secretion assay, chicken neurons were plated on poly-D-lysine pre-coated 24-well plates (BD Biocoat) at a cell density of 1.8 × 106 neurons per 24 well. After 48 h, culture medium was exchanged, and neurons were incubated for 24 h with different concentrations of compounds in a total volume of 300 μl culture medium. For the MTT viability assay, neurons were plated on poly-D-lysine pre-coated 96-well plates (BD Biocoat) at a cell density of 3 × 105 neurons per 96 well in a total volume of 160 μl culture medium.
A human neuroglioma H4 cell line stably transfected with the pAG3 vector containing human APP695 with the Swedish double mutation K595N/M596L was used as cell line model (Haugabook et al. 2001). The pAG3 vector is a modified pcDNA3 plasmid and contains the hygromycin-B resistance cassette with the transgene under the control of a fused CMV and chicken β-actin promoter. H4 cells were plated on 96-well plates (BD) at a cell density of 1 × 104 cells per 96 well in 160 μl OptiMEM (Invitrogen) containing 10% fetal bovine serum, 1% penicillin/streptomycin, 200 μg/ml hygromycin-B (Roth), and 2.5 μg/ml blasticidin-S (BioChemika). After 48 h, culture medium was exchanged and neurons were incubated for 24 h with different concentrations of compounds in a total volume of 60 μl culture medium. All cultures were kept at 37°C and 5% CO2. Viability of cultures was determined by the MTT assay (Gutmann et al. 2002).
After treatment, cell supernatants were snap frozen at −80°C and defrosted prior to Aβ measurement. At least three separate wells were analyzed per experiment for each condition.
Cell supernatants were examined for Aβ38, Aβ40, and Aβ42 content with a commercially available Aβ-Triplex kit from Mesoscale Discovery (MSD). Conditioned media of primary chicken telencephalic cultures were measured undiluted, whereas supernatants of H4 cells were diluted 1:10 with culture medium prior to measurement. For capture, Aβ38, Aβ40, and Aβ42 specific antibodies binding the C-terminus of the corresponding Aβ peptide (provided by MSD) were used. Bound Aβ peptides were detected with a monoclonal 6E10 antibody and quantified by electrochemiluminescence. Aβ levels in cell supernatants were evaluated in comparison to an Aβ peptide standard in picogram or nanogram per milliliter. Vehicle-treated control cultures were set as 100%. All data of compound-treated cultures are displayed in relation to vehicle-treated controls as mean ± standard error of mean. The total Aβ content was calculated as sum of Aβ38, Aβ40, and Aβ42.
GraphPad Prism (GraphPad Software, Inc., San Diego, CA) was used to graph and analyze data.
Chicken embryos express endogenous APP in the developing telencephalon and also the required enzymes for Aβ formation (Carrodeguas et al. 2005). Hence, we first determined the amount of Aβ38, Aβ40, and Aβ42 being released into the cell supernatant by primary E8 chicken telencephalic neurons and H4 cells stably expressing human APPK595N/M596L.
Primary chicken neurons were cultured in 24-well plates at high cell density for 48 h. For determining Aβ production, 300 μl of fresh medium were applied for 24 h. H4 cells overexpressing human APPK595N/M596L were plated in 96-well plates and grown to 80–90% confluency. Cells were then incubated with 60 μl of fresh medium for 24 h. Conditioned media of cultures were then analyzed for all three Aβ analytes using a Triplex immunosorbent assay.
Both culture systems released Aβ38, Aβ40, and Aβ42 peptides at detectable levels (Fig. 1a, b). H4 cells overexpressing human APPK595N/M596L secreted 1.7 ± 0.1 ng/ml Aβ38, 24 ± 1.0 ng/ml Aβ40, and 1.9 ± 0.1 ng/ml Aβ42 (27.8 ± 1.0 ng/ml total Aβ), whereas primary telencephalic neurons produced 0.11 ± 0.01 ng/ml Aβ38, 1.37 ± 0.06 ng/ml Aβ40, and 0.17 ± 0.01 ng/ml Aβ42 (1.64 ± 0.08 ng/ml total Aβ). The Aβ content in cell free culture medium was negligible (data not shown). Thus, the H4 cell line produced at least tenfold more Aβ peptides than primary telencephalic chicken neurons.
However, the relative abundance of different Aβ peptides was comparable between cultures of primary neurons and the H4 cell line. The main Aβ species detected in conditioned media was Aβ40, which comprised more than 80% of all analyzed Aβ forms. Aβ38 and Aβ42 were produced considerably less than Aβ40 but both in similar quantities at approximately 7–10%. Importantly, the relative abundance of Aβ peptides in both culture systems correlates with results from previously described primary chicken telencephalic cultures (Esselmann et al. 2004). Hence, primary chicken telencephalic neurons and H4 cells stably transfected with human APPK595N/M596L produced sufficient amounts of Aβ38, Aβ40, and Aβ42 peptides and could be used for further analysis.
To compare the effect of drugs modulating or inhibiting the generation of Aβ38, Aβ40, and Aβ42 peptides in cultures of primary chick neurons and in the H4 neuroglioma cell line, we examined already characterized β- and γ-secretase inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), and a calpain inhibitor. Almost all of the selected compounds were demonstrated to alter APP processing but not total APP protein levels (Dovey et al. 2001; Weggen et al. 2001; Mathews et al. 2002; Na et al. 2007). Hence, supernatants of compound-treated cultures were analyzed for their Aβ38, Aβ40, and Aβ42 content by an immunosorbent assay assuming that total APP levels remained unaffected. Viability of cultures was assessed in a colorimetric MTT assay. The respective IC50 and Emax of each compound are summarized in Table 1.
First, we examined the β-secretase inhibitor IV, a commercially available BACE-1 inhibitor, which has been previously shown to inhibit BACE-1 in a HEK cell culture model overexpressing APPNFEV at an IC50 of 15 nM (Stachel et al. 2004). When the β-secretase inhibitor IV was applied on the H4 cell line, a concentration-dependent decrease in Aβ secretion (IC50 Aβ38 = 92.3 nM, IC50 Aβ40 = 124.7 nM, IC50 Aβ42 = 215.6 nM) was evident (Fig. 2a), but the reduction occurred at distinctly higher concentrations than in the HEK cell culture model (Stachel et al. 2004). In contrast, the Aβ38, Aβ40, and Aβ42 content declined in primary neuronal cultures already at 5 nM (Fig. 2b), and Aβ42 was reduced by more than 50% at an inhibitor concentration of 25 nM, indicating that the extent of inhibition in telencephalic neurons complies with the reported IC50 in HEK cells (Stachel et al. 2004). Unexpectedly, Aβ40 and Aβ42 production was not completely inhibited by the BACE-1 inhibitor (Table 1). The effect of the β-secretase inhibitor on Aβ cleavage was not due to compound toxicity as no reduction in cell viability was observed (data not shown). Altogether, BACE-1 inhibition was approximately tenfold more potent in primary cells than in the human neuroglioma cell line expressing human APPK595N/M596L.
Next, we addressed the effect of two γ-secretase inhibitors, DAPM and DAPT, in our two culture models. DAPM was shown to reduce secretion of Aβ monomers in CHO cells expressing human APP751Val717Phe at an IC50 of approximately 100 nM by a highly sensitive immunoprecipitation and western blotting method (Walsh et al. 2002). DAPT was reported to abolish Aβ42 formation in primary human neuronal cultures at an IC50 of 200 nM (Dovey et al. 2001).
DAPM reduced secretion of all three Aβ species in H4 cells (IC50 Aβ38 = 19.9 nM, IC50 Aβ40 = 23.1 nM, IC50 Aβ42 = 25.9 nM) but conversely caused an increase of all three Aβ forms at low nanomolar concentrations (Fig. 3a). In cultures of primary telencephalic neurons, DAPM also decreased formation of Aβ peptides (IC50 Aβ38 = 61.9 nM, IC50 Aβ40 = 99.7 nM, IC50 Aβ42 = 106.9 nM) but at higher concentrations than in H4 cultures. Also, no increase in Aβ secretion was observed in primary cultures at any concentration of the γ-secretase inhibitor (Fig. 3b). Hence, the effect of DAPM was slightly more potent in H4 cells overexpressing human APPK595N/M596L than in primary telencephalic neurons. DAPM had no effect on cell viability in both culture systems (data not shown).
The second γ-secretase inhibitor, DAPT, inhibited APP cleavage in H4 cells (IC50 Aβ38 = 50.3 nM, IC50 Aβ40 = 61.4 nM, IC50 Aβ42 = 63.8 nM) but also increased the formation of all three Aβ species at 10 nM (Fig. 4a). Similarly, Aβ38, Aβ40, and Aβ42 peptide levels decreased in supernatants of primary neurons (IC50 Aβ38 = 71.2 nM, IC50 Aβ40 = 92.8 nM, IC50 Aβ42 = 100.8 nM), but no dramatic increase in Aβ levels was observed at low nanomolar concentrations of the compound in contrast to H4 cells (Fig. 4b). Viability of primary neurons and H4 cells was not affected by DAPT treatment (data not shown). As in DAPM treated cultures, the effect of DAPT was slightly more pronounced in H4 cells stably expressing human APPK595N/M596L than in primary telencephalic neurons. However, the IC50 of DAPT and DAPM for Aβ42 cleavage was not higher in primary neurons when compared to the published efficacies of these inhibitors. Hence, both culture systems reproduced the reported effects of the selected γ-secretase inhibitors.
A subset of non-steroidal anti-inflammatory drugs (NSAIDs) has been shown to interfere with APP processing by modulating γ-secretase-mediated APP cleavage independent of their impact on cyclooxygenase-1 (COX1) and COX2 activity (Weggen et al. 2001). Here, we investigated the effect of sulindac sulfide and CW in our cell culture models. The non-selective COX-inhibitor sulindac sulfide has previously been reported to reduce Aβ42 levels by ≥50% at concentrations of 80–100 μM in several cell lines overexpressing human wildtype or mutant APP (Weggen et al. 2001). Concomitant with the decrease in Aβ42 content, an increase in Aβ38 was detected in supernatants of treated cultures (Weggen et al. 2001). In CHO cells expressing human APP containing the Swedish mutation, 40 μM sulindac sulfide reduced Aβ42 secretion to ~45% (Weggen et al. 2003). The second NSAID we examined was the cell-permeable benzoate CW, which was identified in a computer-based structural similarity search for NSAIDs. CW has been demonstrated to reduce Aβ42 levels at a concentration of 100 μM (Okochi et al. 2006).
In H4 cells expressing human APPK595N/M596L, sulindac sulfide enhanced generation of Aβ38 peptides at low micromolar concentration (Fig. 5a). A decrease in Aβ42 levels appeared at a concentration of 50 μM with Aβ42 levels being reduced to 75.0 ± 7.1%. The Aβ42 content declined further to 39.3 ± 2.0% at 100 μM, whereas Aβ40 production remained still unaltered. At 150 μM, sulindac sulfide started to display already some minor cell toxicity in the viability assay (data not shown). Thus, the concentration of sulindac sulfide necessary to diminish Aβ42 levels by 50% was between 75 and 100 μM. The different extent of sulindac sulfide-mediated modulation of Aβ38 and Aβ42 levels was not unexpected. Analyses of different PS1 mutations associated with familial Alzheimer's disease (FAD) revealed that sulindac sulfide can modulate Aβ38 and Aβ42 formation independently (Page et al. 2008).
In contrast to H4 cells, secretion of Aβ42 peptides was already reduced at lower micromolar concentrations of sulindac sulfide in primary neuronal cultures (Fig. 5b). Aβ38 content started to increase at 25 μM to approximately 149.7 ± 6.4%, whereas Aβ42 levels decreased concomitantly to 54.7 ± 6.4%. At 50 μM, Aβ38 levels did not rise any further, but Aβ42 continued to drop to 25.3 ± 2.1%, and also Aβ40 levels started to decline. At concentrations beginning with 75 μM, the NSAID started to become toxic in primary cultures (data not shown). Hence, the concentration of sulindac sulfide required to reduce Aβ42 levels in primary chick cultures by 50% is at ~33 μM. This also complies with the efficacy of sulindac sulfide described in HEK cell (Weggen et al. 2003), whereas sulindac sulfide was surprisingly less efficacious in the stable H4 cell line expressing human APPK595N/M596L.
CW started to elevate Aβ38 and moderately reduce Aβ42 levels in H4 cells at a concentration of 50 μM (Fig. 6a). At 100 μM, Aβ38 increased to 287.5 ± 31.2%, whereas Aβ42 was further reduced to 16.0 ± 1.8% compared to vehicle-treated cultures. At 150 and 200 μM, Aβ38 and Aβ40 secretion started also to decline, although no cell toxicity was observed in the MTT viability assay at these concentrations (data not shown). Therefore, CW decreased Aβ42 levels in H4 cells by 50% at concentrations between 50 and 100 μM.
In cultures of primary telencephalic neurons, moderate changes in Aβ38 and Aβ42 peptide were already detected at 5 μM CW (Fig. 6b). At 10 μM, an increase of 127.9 ± 0.9% Aβ38 was observed, whereas Aβ42 levels declined to 63.6 ± 2.4%. The effect of CW was further potentiated at 50 μM, with Aβ38 levels rising to 159.3 ± 8.0% and Aβ42 falling to 29.9 ± 1.2%. Therefore, CW diminished Aβ42 levels by 50% at ~17 μM in primary neurons. The Aβ40 content remained unchanged up to 50 μM compared to vehicle-treated cells. However, starting from 100 μM, levels of all Aβ species declined progressively with increasing concentration of the NSAID. The reduction of Aβ species at the two highest concentrations was due to neuronal toxicity of the compound as CW affected cell viability at 150 and 200 μM but not at lower concentrations (data not shown). As sulindac sulfide, CW was also more efficacious in modulating APP processing in primary telencephalic neurons than in the H4 cell line ectopically expressing human mutant APP.
An unregulated intracellular increase of Ca2+ and elevated activity of the Ca2+-dependent calpain proteases has been linked with inducing cell death (Harwood et al. 2005; Golstein and Kroemer 2007). Further, calpain inhibitors have been demonstrated to counteract excitotoxic insults (Hara and Snyder 2007). But besides their role in cell death, calpains have also been implicated in APP processing since inhibition of calpain activity was demonstrated to increase Aβ42 production in cell cultures (Klafki et al. 1996; Zhang et al. 1999; Mathews et al. 2002). The cell-permeable calpain inhibitor calpeptin has been reported to elevate secretion of Aβ42 but not of Aβ40 at a concentration of 10 μM in a murine cell line ectopically expressing human wildtype APP695 and also in untransfected murine cells (Mathews et al. 2002).
Calpeptin did not evoke any dramatic changes in H4 cells expressing mutant human APP up to a concentration of 1 μM (Fig. 7a). However, at 10 μM, Aβ38 (12.9 ± 2.6%) and Aβ40 (35.5 ± 2.2%) peptide levels decreased sharply, whereas Aβ42 (90.3 ± 6.0%) remained almost on the same level as in vehicle control cultures.
Similarly, no effect of calpeptin was observed in cultures of primary chicken neurons up to a concentration of 1 μM (Fig. 7b). In contrast to H4 cells, calpeptin increased Aβ42 levels to 259.3 ± 7.3% at a concentration of 10 μM, whereas Aβ40 remained almost unchanged at 89.9 ± 3.8%. The Aβ38 content in supernatants was reduced to 31.1 ± 1.8%. No toxicity of calpeptin was observed in primary and H4 cell cultures (data not shown). Hence, primary telencephalic neurons but not H4 cells expressing human APPK595N/M596L increased Aβ42 generation at a calpeptin concentration of 10 μM. Therefore, primary chicken neurons but not H4 cells reproduced the previously reported effect of calpeptin on APP processing (Mathews et al. 2002).
Increased formation of toxic Aβ42 peptides is characteristic for sporadic and familial forms of Alzheimer's disease. Therefore, compounds targeting β- and γ-secretase activities were developed in recent years to render formation of aberrant Aβ42. Most in vitro screens identifying such compounds were performed in immortalized cells expressing mutant human APP. Here, we compared primary chicken telencephalic neurons with a human neuroglioma cell line overexpressing human APP harboring the Swedish double mutation to decipher differences in their response to known modulators of APP processing.
We chose chicken telencephalic rather than rodent neurons as source for primary cultures since chick Aβ42 is identical to the human sequence and primary chicken telencephalic neurons were previously demonstrated to secrete detectable amounts of Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40, and Aβ1-42 in vitro by using an immunoprecipitation and Western Blot protocol (Esselmann et al. 2004). In accordance, we confirmed formation of Aβ38, Aβ40, and Aβ42 peptides in cell supernatants of primary chicken telencephalic neurons using an electrochemiluminescence based immunosorbent assay. Similar to human cerebrospinal fluid (Lewczuk et al. 2004), Aβ40 was the predominant Aβ species produced by primary chicken neurons and the neuroglioma cell line. H4 cells overexpressing human mutant APP secreted at least tenfold more Aβ peptides than chicken neurons, but the Aβ42/Aβ40 ratio was comparable in supernatants of H4 cells and primary telencephalic neurons.
Since both culture systems produced desirable levels of Aβ peptides, we administered compounds known to inhibit or modulate APP cleavage and determined production of Aβ38, Aβ40, and Aβ42 peptides.
In cultures treated with the β-secretase inhibitor IV, we observed a more severe inhibition of β-secretase activity in primary neurons than in the H4 cell line expressing human APP harboring the Swedish double mutation. This appears particularly interesting as this mutation has been associated with accelerated APP cleavage by β-secretase. Other groups also demonstrated that BACE-1 inhibition is approximately tenfold less powerful in cells expressing human APPK595N/M596L compared to cells overexpressing wildtype APP (Hussain et al. 2007; Yamakawa et al. 2010). Recently, the difference in β-secretase inhibition has been linked to different subcellular localization of wildtype APP and APPK595N/M596L (Koo and Squazzo 1994; Haass et al. 1995; Yamakawa et al. 2010). Similarly, the FAD-linked mutations APPV717F, PS1M146L, and PS1L166P, which all affect γ-secretase cleavage, are less sensitive to γ-secretase inhibitors (Xia et al. 2000; Czirr et al. 2007). Moreover, cells transfected with APPV717F or different PS1 mutations display altered secretion of Aβ peptides in response to sulindac sulfide treatment compared to cells transfected with the respective wildtype protein (Weggen et al. 2003; Czirr et al. 2007; Page et al. 2008). Thus, secretase inhibitors and modulators exhibit different potencies and effects in cellular assays depending on the presence or absence of FAD-linked mutations. Since the vast majority of patients who suffer from sporadic AD encode wildtype and not mutant APP or PS1, screening compounds in cells expressing wildtype APP and PS1 reflects more on human pathology and also defines the efficacy of a substance more precisely.
Both γ-secretase inhibitors, DAPM and DAPT, evoked a dose-dependent decrease in Aβ38, Aβ40, and Aβ42 levels, but the reduction was more pronounced in the neuroglioma cell line than in primary telencephalic neurons. Indeed, DAPT has been demonstrated to inhibit Aβ formation more severely in a HEK293 cell line expressing human APP751 containing the Swedish mutation than in primary neuronal cultures with DAPT exhibiting a five- to tenfold lower potency in human and mouse primary cultures (Dovey et al. 2001). Similarly to DAPT, a selective tyrosine kinase inhibitor, which has been suggested to indirectly regulate γ-secretase activity, reduced Aβ production faster in N2a cells producing Swedish mutant APP than in primary cortical neurons (Netzer et al. 2003). As β-secretase cleavage is a pre-requisite for γ-secretase-mediated APP processing, APP containing the Swedish mutation simply increases the intracellular concentration of γ-secretase substrate and thus provides a higher and more favorable substrate/enzyme ratio than in primary neurons (Citron et al. 1992; Yang et al. 2003). Subsequently, an enzymatic reaction at a high substrate/enzyme ratio enables a more efficient inhibition of APP cleavage by secretase inhibitors. A comparison of γ-secretase inhibitors in cell lines expressing either wildtype or APP containing the Swedish mutation would address the influence of Swedish mutant APP on γ-secretase inhibition. When DAPT was administered in vivo, the actual concentration of DAPT in brain tissue (~200 nM and higher) that reduced total Aβ content was in excess of the IC50 in primary cultures (IC50 Aβ total = 115 nM) (Dovey et al. 2001). Thus, in vivo DAPT data indicate that primary neurons are more likely to define the potency of a γ-secretase inhibitor for in vivo administration than cell lines. Beside the reduction in Aβ levels, we also observed an increase in Aβ38, Aβ40, and Aβ42 formation at DAPM and DAPT concentrations below their respective IC50. Such an effect has already been described for a difluoroketoamide-based γ-secretase inhibitor, which also increased Aβ42 levels at sub-inhibitory concentrations (Durkin et al. 1999).
In contrast, modulation of γ-secretase activity by NSAIDs appeared more severe in primary cultures. A comparison of N2a cells expressing human APP bearing the Swedish mutation and primary rat cortical neurons also indicated a stronger reduction of Aβ40 and Aβ42 levels in primary cultures at a concentration of 25 μM (Gasparini et al. 2004), although we only observed a reduction in Aβ40 levels at very high sub-lethal and lethal concentrations. The reduced potency of NSAIDs in the neuroglioma cell line is, unlike BACE-1 inhibitors, independent of the APP Swedish double mutation. CHO cells transfected with APPK595N/M596L secrete the same levels of Aβ42 after treatment with sulindac sulfide as cells expressing wildtype APP (Weggen et al. 2003). However, primary neurons and cell lines differ in their APP content. Whereas primary neurons produce endogenous APP at physiological levels, cell lines highly overexpress ectopic APP suggesting that the modulating activity of NSAIDs is dependent on the amount and availability of APP substrate. Such a scenario would assume that sulindac sulfide and CW directly interact with APP. Indeed, a study using labeled γ-secretase modulators (GSM) revealed a direct interaction of GSMs with residues of the beta-amyloid peptide rather than with the core proteins of the γ-secretase complex (Kukar et al. 2008). Hence, total APP levels can be critical for the potency of NSAIDs. Besides their higher sensitivity for APP modulation, primary neurons are also more prone to cell toxicity mediated by NSAIDs and give, in addition to APP processing, valuable information on the neurotoxicity of substances.
Further, we analyzed the calpain inhibitor calpeptin in our culture models. Interestingly, we replicated the Aβ42 increasing effect of calpeptin in primary cultures but not in the H4 cell line although the modulating activity of calpeptin was initially demonstrated in a murine fibroblast-like cell line and in murine and human neuroblastoma cells (Mathews et al. 2002). Hence, the lack of effect of calpeptin in H4 cells can be attributed at least in parts to the nature of the H4 neuroglioma cell line. This finding highlights the problem that most data on APP processing has been generated in a variety of different cell lines and hence a comparison between cellular assays proves difficult. Some cell lines originate from non-neuronal cell types, whereas others are from different species. Also, the expression of various FAD-linked mutations in cell lines does not allow a comprehensive comparison of secretase inhibitors and modulators. Therefore, the use of a unifying cell culture system such as primary neurons would be of advantage to allow a direct comparison of APP modifying substances.
In conclusion, primary telencephalic chicken neurons are a well-suited cell culture model for testing drugs targeting Aβ formation. Primary chicken neurons produce endogenous levels of wildtype APP and PS1 and secrete Aβ peptides which are identical in their sequence to human Aβ and thus reflect the molecular condition of sporadic Alzheimer's disease. In addition, primary telencephalic neurons are overall more sensitive to pharmacological intervention than immortalized cell lines with the exception of γ-secretase inhibitors and in sum define the potency and mechanism of drugs more accurately regarding their in vivo efficacy and toxicity. For drug discovery, primary neurons expressing wildtype APP are a suitable system to model sporadic Alzheimer's disease. In contrast, cell lines producing proteins containing FAD-linked mutations exhibit a model for testing drugs targeting familial forms of AD.
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
|Carrodeguas JA,Rodolosse A,Garza MV,et al. The chick embryo appears as a natural model for research in beta-amyloid precursor protein processingNeuroscienceYear: 20051341285130010.1016/j.neuroscience.2005.05.02016039787|
|Citron M,Oltersdorf T,Haass C,et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein productionNatureYear: 199236067267410.1038/360672a01465129|
|Citron M,Teplow DB,Selkoe DJ. Generation of amyloid beta protein from its precursor is sequence specificNeuronYear: 19951466167010.1016/0896-6273(95)90323-27695913|
|Cole SL,Vassar R. The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiologyJ Biol ChemYear: 2008283296212962510.1074/jbc.R80001520018650431|
|Czirr E,Leuchtenberger S,Dorner-Ciossek C,et al. Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutationsJ Biol ChemYear: 2007282245042451310.1074/jbc.M70061820017573346|
|Dahlgren KN,Manelli AM,Stine WB,et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viabilityJ Biol ChemYear: 2002277320463205310.1074/jbc.M20175020012058030|
|Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking point on the role of presenilin mutations in Alzheimer diseaseEMBO RepYear: 2007814114610.1038/sj.embor.740089717268505|
|Dovey HF,John V,Anderson JP,et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brainJ NeurochemYear: 20017617318110.1046/j.1471-4159.2001.00012.x11145990|
|Durkin JT,Murthy S,Husten EJ,et al. Rank-order of potencies for inhibition of the secretion of abeta40 and abeta42 suggests that both are generated by a single gamma-secretaseJ Biol ChemYear: 1999274204992050410.1074/jbc.274.29.2049910400678|
|Esselmann H,Maler JM,Kunz N,et al. Lithium decreases secretion of Abeta1-42 and C-truncated species Abeta1-37/38/39/40 in chicken telencephalic cultures but specifically increases intracellular Abeta1-38Neurodegener DisYear: 2004123624110.1159/00008099216908996|
|Gasparini L,Rusconi L,Xu H,et al. Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell culturesJ NeurochemYear: 20048833734810.1111/j.1471-4159.2004.02154.x14690522|
|Ghosh AK,Gemma S,Tang J. Beta-secretase as a therapeutic target for Alzheimer's diseaseNeurotherapeuticsYear: 2008539940810.1016/j.nurt.2008.05.00718625451|
|Golstein P,Kroemer G. Cell death by necrosis: towards a molecular definitionTrends Biochem SciYear: 200732374310.1016/j.tibs.2006.11.00117141506|
|Gutmann B,Hutter-Paier B,Skofitsch G,et al. In vitro models of brain ischemia: the peptidergic drug cerebrolysin protects cultured chick cortical neurons from cell deathNeurotox ResYear: 20024596510.1080/1029842029000763712826494|
|Haass C. Take five—BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generationEmbo JYear: 20042348348810.1038/sj.emboj.760006114749724|
|Haass C,Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptideNat Rev Mol Cell BiolYear: 2007810111210.1038/nrm210117245412|
|Haass C,Lemere CA,Capell A,et al. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathwayNat MedYear: 199511291129610.1038/nm1295-12917489411|
|Hara MR,Snyder SH. Cell signaling and neuronal deathAnnu Rev Pharmacol ToxicolYear: 20074711714110.1146/annurev.pharmtox.47.120505.10531116879082|
|Hardy J,Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeuticsScienceYear: 200229735335610.1126/science.107299412130773|
|Harwood SM,Yaqoob MM,Allen DA. Caspase and calpain function in cell death: bridging the gap between apoptosis and necrosisAnn Clin BiochemYear: 20054241543110.1258/00045630577453823816259792|
|Haugabook SJ,Yager DM,Eckman EA,et al. High throughput screens for the identification of compounds that alter the accumulation of the Alzheimer's amyloid beta peptide (Abeta)J Neurosci MethodsYear: 200110817117910.1016/S0165-0270(01)00388-011478976|
|Hussain I,Hawkins J,Harrison D,et al. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivoJ NeurochemYear: 200710080280910.1111/j.1471-4159.2006.04260.x17156133|
|Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulatorsCurr Top Med ChemYear: 20088546110.2174/15680260878333401518220933|
|Klafki H,Abramowski D,Swoboda R,et al. The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activitiesJ Biol ChemYear: 1996271286552865910.1074/jbc.271.45.286558910499|
|Koo EH,Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathwayJ Biol ChemYear: 199426917386173898021238|
|Kukar TL,Ladd TB,Bann MA,et al. Substrate-targeting gamma-secretase modulatorsNatureYear: 200845392592910.1038/nature0705518548070|
|Leuchtenberger S,Maler J,Czirr E,et al. Nonsteroidal anti-inflammatory drugs and ectodomain shedding of the amyloid precursor proteinNeurodegener DisYear: 200961810.1159/00012139118349521|
|Lewczuk P,Esselmann H,Otto M,et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tauNeurobiol AgingYear: 20042527328110.1016/S0197-4580(03)00086-115123331|
|Mathews PM,Jiang Y,Schmidt SD,et al. Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of calpains enhances endosomal generation of beta-cleaved C-terminal APP fragmentsJ Biol ChemYear: 2002277364153642410.1074/jbc.M20520820012087104|
|Mullan M. Familial Alzheimer's disease: second gene locus locatedBmjYear: 19923051108110910.1136/bmj.305.6862.11081463941|
|Mullan M,Houlden H,Windelspecht M,et al. A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin geneNat GenetYear: 1992234034210.1038/ng1292-3401303291|
|Na CH,Jeon SH,Zhang G,et al. Inhibition of amyloid beta-peptide production by blockage of beta-secretase cleavage site of amyloid precursor proteinJ NeurochemYear: 20071011583159510.1111/j.1471-4159.2006.04441.x17542811|
|Netzer WJ,Dou F,Cai D,et al. Gleevec inhibits beta-amyloid production but not Notch cleavageProc Natl Acad Sci U S AYear: 2003100124441244910.1073/pnas.153474510014523244|
|Okochi M,Fukumori A,Jiang J,et al. Secretion of the Notch-1 Abeta-like peptide during Notch signalingJ Biol ChemYear: 20062817890789810.1074/jbc.M51325020016434391|
|Page RM,Baumann K,Tomioka M,et al. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulationJ Biol ChemYear: 200828367768310.1074/jbc.M70875420017962197|
|Pettmann B,Louis JC,Sensenbrenner M. Morphological and biochemical maturation of neurones cultured in the absence of glial cellsNatureYear: 197928137838010.1038/281378a039256|
|Sarasa M,Pesini P. Natural non-transgenic animal models for research in Alzheimer's diseaseCurr Alzheimer ResYear: 2009617117810.2174/15672050978760283419355852|
|Silvestri R. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's diseaseMed Res RevYear: 20092929533810.1002/med.2013218651582|
|Stachel SJ,Coburn CA,Steele TG,et al. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1)J Med ChemYear: 2004476447645010.1021/jm049379g15588077|
|Walsh DM,Selkoe DJ. A beta oligomers—a decade of discoveryJ NeurochemYear: 20071011172118410.1111/j.1471-4159.2006.04426.x17286590|
|Walsh DM,Klyubin I,Fadeeva JV,et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivoNatureYear: 200241653553910.1038/416535a11932745|
|Weggen S,Eriksen JL,Das P,et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activityNatureYear: 200141421221610.1038/3510259111700559|
|Weggen S,Eriksen JL,Sagi SA,et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activityJ Biol ChemYear: 2003278318313183710.1074/jbc.M30359220012805356|
|Wolfe MS. The gamma-secretase complex: membrane-embedded proteolytic ensembleBiochemistryYear: 2006457931793910.1021/bi060799c16800619|
|Wolfe MS. Gamma-secretase inhibition and modulation for Alzheimer's diseaseCurr Alzheimer ResYear: 2008515816410.2174/15672050878395476718393800|
|Xia W,Ostaszewski BL,Kimberly WT,et al. FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complexNeurobiol DisYear: 2000767368110.1006/nbdi.2000.032211114265|
|Yamakawa H,Yagishita S,Futai E,et al. Beta-secretase inhibitor potency is decreased by aberrant beta-cleavage location of the "Swedish mutant" amyloid precursor proteinJ Biol ChemYear: 20102851634164210.1074/jbc.M109.06675319926793|
|Yang LB,Lindholm K,Yan R,et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer diseaseNat MedYear: 200393410.1038/nm0103-312514700|
|Zhang L,Song L,Parker EM. Calpain inhibitor I increases beta-amyloid peptide production by inhibiting the degradation of the substrate of gamma-secretase. Evidence that substrate availability limits beta-amyloid peptide productionJ Biol ChemYear: 19992748966897210.1074/jbc.274.13.896610085142|
Effects of pharmacological modulators on Aβ formation
|Beta secretase inhibitor IV||H4 cells—hAPPK595N/N596L||92 nM||88%||125 nM||79%||216 nM||86%|
|Primary chicken neurons||3.7 nM||91%||4.7 nM||76%||4.8 nM||70%|
|DAPM||H4 cells—hAPPK595N/N596L||20 nM||100%||23 nM||100%||26 nM||100%|
|Primary chicken neurons||62 nM||100%||100 nM||100%||107 nM||100%|
|DAPT||H4 cells—hAPPK595N/N596L||50 nM||100%||61 nM||100%||64 nM||100%|
|Primary chicken neurons||71 nM||100%||93 nM||100%||101 nM||100%|
|Sulindac sulfide||H4 cells—hAPPK595N/N596L||–||–||–||–||76 μM||100%|
|Primary chicken neurons||–||–||–||–||33 μM||100%|
|CW||H4 cells—hAPPK595N/N596L||–||–||–||–||41 μM||100%|
|Primary chicken neurons||–||–||–||–||17 μM||100%|
|Calpeptin||H4 cells—hAPPK595N/N596L||4.0 μM||100%||7.4 μM||100%||–||–|
|Primary chicken neurons||5.0 μM||100%||–||–||–||–|
The IC50 and Emax values for Aβ38, Aβ40, and Aβ42 generation in H4 cells overexpressing human APPK595N/M596L and in primary telencephalic chicken neurons are summarized for each individual compound
Keywords: Keywords Alzheimer's disease, Aβ secretion, Culture model, Secretase, Drug testing.
Previous Document: Factors associated with spatial clustering of foot-and-mouth disease in Nepal.
Next Document: A Re-evaluation of the "Oncogenic" Nature of Wnt/beta-catenin Signaling in Melanoma and Other Cancer...